Search
Linagliptin
go.drugbank.com/drugs/DB08882ApprovedInvestigationalLinagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated b...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesFormestane
go.drugbank.com/drugs/DB08905ApprovedWithdrawnFormestane was the first selective, type I, steroidal aromatase inhibitor used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women. Formestane suppresses estrogen production from anabolic steroids or pro...
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersFluticasone furoate
go.drugbank.com/drugs/DB08906ApprovedInvestigationalFluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label] . Fluticasone furoate was first approved in 2007 .
Categories: P-glycoprotein inducers, P-glycoprotein substratesIndenolol
go.drugbank.com/drugs/DB08952ApprovedWithdrawnIndenolol is a drug of the beta-adrenergic blocker class.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesFendiline
go.drugbank.com/drugs/DB08980ApprovedWithdrawnFendiline is a coronary vasodilator which inhibits calcium function in muscle cells in excitation-contraction coupling. It has been proposed as an antiarrhythmic and antianginal agent. Fendiline is non-selective.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesIbrutinib
go.drugbank.com/drugs/DB09053ApprovedInvestigationalIbrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibruti...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesUmeclidinium
go.drugbank.com/drugs/DB09076ApprovedInvestigationalUmeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath,...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesCiglitazone
go.drugbank.com/drugs/DB09201ExperimentalDeveloped by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class. Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones....
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsTolfenamic acid
go.drugbank.com/drugs/DB09216ApprovedTolfenamic acid, with the formula N-(2-methyl-3-chlorphenyl)-anthranilic acid, is a nonsteroidal anti-inflammatory agent.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBlonanserin
go.drugbank.com/drugs/DB09223InvestigationalBlonanserin is an atypical antipsychotic approved in Japan in January, 2008. It offers improved tolerability as it lacks side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. As a second-generation (atypical) ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates